Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Gains from Investment Securities (2016 - 2025)

Sangamo Therapeutics (SGMO) has 15 years of Gains from Investment Securities data on record, last reported at -$2.7 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 462.26% year-over-year to -$2.7 million; the TTM value through Sep 2025 reached $987000.0, up 139.18%, while the annual FY2024 figure was $1.0 million, 191.69% up from the prior year.
  • Gains from Investment Securities reached -$2.7 million in Q3 2025 per SGMO's latest filing, down from $420000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.2 million in Q1 2025 and bottomed at -$2.7 million in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $113444.4, with a median of $450500.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: tumbled 1266.1% in 2021, then skyrocketed 264.19% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$1.3 million in 2021, then surged by 264.19% to $2.1 million in 2022, then crashed by 220.14% to -$2.5 million in 2023, then skyrocketed by 140.51% to $1.0 million in 2024, then crashed by 362.43% to -$2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$2.7 million in Q3 2025, $420000.0 in Q2 2025, and $2.2 million in Q1 2025.